Abstract PS2-02-01: Improved Antiemetic Outcomes with NEPA vs (Fos)aprepitant in Patients with Breast Cancer Receiving Antibody-Drug Conjugates: A 12-Month Real-World Claims Analysis
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: L. Schwartzberg, T. Gillespie, E. Roeland, T. Tyler, R. Agarwal, A. Alonzi, T. Fralich, P. Mudumby, G. Aweh, M. Fisher, H. Rugo
Institutions: Renown Health, Emory University, Winship Cancer Institute, Oregon Health & Science University, Desert Regional Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Helsinn (Switzerland), Helsinn Therapeutics (United States), STATinMED (United States), City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129370297
Cites:
Cited by:
Related to: